Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.
Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti, Giulia Francesca Manfredi, George Merces, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas Urban Marron, Anwaar Saeed, Matthias Pinter, , David James Pinato
This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.
bioRxiv · Jul 8, 2025 · PreprintCancer Biology